M 1743 Pill — ORANGE OVAL, 19mm — Ciprofloxacin
| Imprint | M / 1743 |
|---|---|
| Colour | ORANGE |
| Shape | OVAL |
| Size | 19 |
| Strength | CIPROFLOXACIN HYDROCHLORIDE 287.5 mg;CIPROFLOXACIN 212.6 mg |
| Dosage form | Tablet, Film Coated, Extended Release |
| Manufacturer | Mylan Pharmaceuticals Inc. |
| NDC | 0378-1743 |
| Schedule | — |
| Availability | — |
| Ingredients | CIPROFLOXACIN HYDROCHLORIDE[CIPROFLOXACIN];CIPROFLOXACIN[CIPROFLOXACIN] |
What does this imprint mean?
The imprint "M 1743" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.
Active ingredient
Ciprofloxacin
Uses and warnings
BOXED WARNING: BOXED WARNING: Fluoroquinolones including ciprofloxacin are "associated with disabling and potentially irreversible serious adverse reactions" including tendinitis/tendon rupture, peripheral neuropathy, and central nervous system effects occurring together. The drug may exacerbate muscle weakness in myasthenia gravis patients and should be avoided in that population. Key Warnings: - Discontinue immediately upon experiencing serious adverse reactions - Risk of tendon rupture (especially Achilles tendon), particularly in patients over 60, on corticosteroids, or with organ transplants - Peripheral neuropathy with potentially irreversible symptoms - CNS effects: psychiatric reactions, seizures, hallucinations, depression with suicidal ideation - Serious hypersensitivity/anaphylactic reactions possible - Hepatotoxicity including fatal hepatic failure reported - QT interval prolongation and torsade de pointes risk - Aortic aneurysm and dissection risk in elderly patients - C. difficile-associated diarrhea possible | BOXED WARNING: Fluoroquinolones including ciprofloxacin are "associated with disabling and potentially irreversible serious adverse reactions" including tendinitis/tendon rupture, peripheral neuropathy, and central nervous system effects occurring together. The drug may exacerbate muscle weakness in myasthenia gravis patients and should be avoided in that population. Key Warnings: - Discontinue immediately upon experiencing serious adverse reactions - Ris
Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18+ years) and select pediatric patients for treating infections including: skin/skin structure infections, bone and joint infections, complicated intra-abdominal infections, infectious diarrhea, typhoid fever, uncomplicated gonorrhea, inhalational anthrax post-exposure, plague, chronic bacterial prostatitis, lower respiratory tract infections, urinary tract infections, and acute sinusitis. The label emphasizes reserving use for patients with no alternative treatment options for certain conditions like acute uncomplicated cystitis and acute bronchitis exacerbations due to serious adverse risks.
How to identify this pill
- • Check the imprint matches exactly: "M 1743".
- • Confirm the colour (ORANGE) and shape (OVAL).
- • Compare the size (19) against a ruler if possible.
- • When in doubt, confirm with a pharmacist before taking any medication.
Similar-looking pills
OLH 12
ORANGE OVAL · Hydrochlorothiazide
25 GG
ORANGE OVAL · Levothyroxine
HP 247
ORANGE OVAL · Venlafaxine
833 5
ORANGE OVAL · Warfarin
G 32
ORANGE OVAL · Naproxen
VH1
ORANGE OVAL · Hydrochlorothiazide
797
ORANGE OVAL · Divalproex
M 86
ORANGE OVAL · Hydrochlorothiazide
L235
ORANGE OVAL · Hydrochlorothiazide
93 321
ORANGE OVAL · Diltiazem
H 90
ORANGE OVAL · Levetiracetam
833 5
ORANGE OVAL · Warfarin
Other pills of Ciprofloxacin
RX711
WHITE CAPSULE · Ciprofloxacin
Y101
WHITE ROUND · Ciprofloxacin
P 500
WHITE BULLET · Ciprofloxacin
TEVA 5312
WHITE OVAL · Ciprofloxacin
C 95
WHITE ROUND · Ciprofloxacin
P 500
WHITE CAPSULE · Ciprofloxacin
CR 500
WHITE CAPSULE · Ciprofloxacin
P 500
WHITE CAPSULE · Ciprofloxacin
CR 500
WHITE ROUND · Ciprofloxacin
WW 927
WHITE ROUND · Ciprofloxacin
C 94
WHITE CAPSULE · Ciprofloxacin
P 500
WHITE CAPSULE · Ciprofloxacin
Official references
Source: FDA Structured Product Label via NLM Pillbox archive (retired 2021); source file b74ba732-2e46-40e0-b646-e320d09b33a2.xml